Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

vbi vaccines b.v. - antigene di superficie dell'epatite b. - epatite b - vaccini - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologici - lucentis è indicato negli adulti per:il trattamento di neovascolare (bagnato) degenerazione maculare legata all'età (amd), il trattamento delle disabilità visiva a causa di coroideale neovascularisation (cnv)il trattamento della disabilità visiva a causa di edema maculare diabetico (dme)il trattamento della disabilità visiva a causa di edema maculare secondario a occlusione della vena retinica (ramo rvo centrale o rvo).

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - oftalmologici - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - vaccini - twinrix pediatrico è indicato per l'uso in bambini non-immuni, bambini e adolescenti da un anno fino a 15 anni compresi, che sono a rischio sia di infezione da epatite a che di epatite b.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - virus dell'epatite a (inattivato), epatite b antigene di superficie - hepatitis b; hepatitis a; immunization - vaccini - twinrix adult è indicato per l'uso in adulti e adolescenti non immuni di età pari o superiore a 16 anni che sono a rischio sia di infezione da epatite a che di epatite b.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologici - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

İtalya - İtalyanca - Ministero della Salute

ballard medical products - rivestimenti per ottiche

İtalya - İtalyanca - Ministero della Salute

amann ophtalmic instruments - strumentario per oftalmologia - altro